| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5814639 | GILEAD | Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds |
Sep, 2015
(8 years ago) | |
|
US5814639 (Pediatric) | GILEAD | Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds |
Mar, 2016
(8 years ago) | |
| US5914331 | GILEAD | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Jul, 2017
(6 years ago) | |
|
US5914331 (Pediatric) | GILEAD | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Jan, 2018
(6 years ago) | |
| US6642245 | GILEAD | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Nov, 2020
(3 years ago) | |
| US6703396 | GILEAD | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
Mar, 2021
(3 years ago) | |
|
US6642245 (Pediatric) | GILEAD | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
May, 2021
(3 years ago) | |
|
US6703396 (Pediatric) | GILEAD | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
Sep, 2021
(2 years ago) | |
Emtriva is owned by Gilead.
Emtriva contains Emtricitabine.
Emtriva has a total of 8 drug patents out of which 8 drug patents have expired.
Expired drug patents of Emtriva are:
- US5814639
- US5814639*PED
- US5914331
- US5914331*PED
- US6642245
- US6703396
- US6642245*PED
- US6703396*PED
Emtriva was authorised for market use on 02 July, 2003.
Emtriva is available in capsule;oral, solution;oral dosage forms.
Emtriva can be used as treatment of hiv infection.
The generics of Emtriva are possible to be released after 09 September, 2021.
Drugs and Companies using EMTRICITABINE ingredient
Market Authorisation Date: 02 July, 2003
Treatment: Treatment of hiv infection
Dosage: CAPSULE;ORAL; SOLUTION;ORAL
EMTRIVA family patents
